Themis Medicare Limited (IN:THEMISMED)
:THEMISMED
Want to see IN:THEMISMED full AI Analyst Report?
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹179.25
Previous CloseN/A
Volume256.77K
Average Volume (3M)6.87K
Market Cap
₹8.91B
Enterprise Value₹9.85B
Total Cash (Recent Filing)₹189.59M
Total Debt (Recent Filing)₹955.64M
Price to Earnings (P/E)22.9
Beta1.60
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)1.10
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-1.45
Price to Book (P/B)3.39
Price to Sales (P/S)3.37
P/FCF Ratio70.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue ModelThemis earns from finished-dose sales, contract manufacturing and exports, providing multiple durable revenue channels. This mix reduces single-market or product concentration risk, supports utilization of manufacturing assets, and offers stable revenue sources across cycles over 2–6 months and beyond.
High Gross MarginsConsistently high gross margins indicate effective cost control and pricing power in formulation manufacturing. Margins are a structural advantage that support reinvestment in R&D and sales, helping sustain profitability even if topline growth moderates over the medium term.
Improving Cash GenerationOperating cash flows and free cash flow have trended positively after earlier weakness, showing improving conversion of profits into cash. Stronger cash generation enhances the company's ability to fund capex, reduce debt, or support growth initiatives without relying heavily on external financing.
Bears Say
Profitability VolatilityVolatile net margins and the recent decline reduce earnings predictability and complicate long-term planning. Persistent margin swings can weaken retained earnings accumulation, undermine investor confidence, and limit the firm's ability to consistently fund strategic initiatives over the medium term.
Recent Revenue And EPS DeclineMaterial year‑over‑year revenue drop (~22%) and a steep EPS decline signal near‑term demand or execution issues. If these trends persist, they erode scale economics, reduce operating leverage benefits, and constrain cash flow and reinvestment capacity, impairing medium‑term growth prospects.
Rising Debt TrendWhile the balance sheet is broadly stable, a recent uptick in total debt slightly raises leverage risk. Increased leverage can restrict financial flexibility, raise interest expense, and limit capacity to pursue M&A or aggressive growth without strengthening equity or improving cash conversion.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹179.25 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹8.91B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is May 27, 2026 which is in 29 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on Feb 13, 2026. The company reported ₹1.096 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.096.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.48%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹1.096 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.41%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was incorporated in 1969 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Kopran Limited
―
Lincoln Pharmaceuticals Ltd
―
Wanbury Limited
―